Characteristic | Patients with biomarker measurements | Patients without biomarker measurements | P value |
---|---|---|---|
ER positive and/or PR positive (n [%]) | 85 (58%) | 159 (62%) | 0.45a |
Prior adjuvant chemotherapy (n [%]) | 98 (60%) | 161 (56%) | 0.31a |
Objective response (complete or partial; n [%]) | 38 (24%) | 66 (23%) | 0.88a |
Median age (years) | 54.9 | 57.2 | 0.25b |
Median follow up (years) | 8.3 | 8.5 | 0.77b |
Median number of metastatic sites (n) | 1 | 1 | 0.14b |
Median disease-free survival (months) | 19 | 31 | 0.0003b |
Median time to progression (months) | 4.1 | 4.3 | 0.62c |
Median overall survival (months) | 12.6 | 12.3 | 0.81c |